Sydnexis Announces New Data from Phase 3 STAR Trial of SYD-101 Presented at 2026 AAPOS Annual Meeting
DEL MAR, Calif., March 23, 2026 – Sydnexis, Inc., a biopharmaceutical company focused on developing a novel low-dose atropine formulation to treat pediatric progressive myopia (PPM), today announced new data from comprehensive subgroup analyses from the Phase 3 Study of Atropine for the Reduction of Myopia Progression (STAR) trial of SYD-101. The data were presented during an oral session at the 51st Annual Meeting of the […]
Aurion Biotech Appoints World Renowned Cornea Surgeon Marjan Farid, M.D.,to Chair Medical Advisory Board
Seattle, WA; Cambridge, MA; Tokyo, Japan – March 11, 2026 – Aurion Biotech, Inc. (“Aurion”), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working toward a future where blindness is eliminated, today announced the appointment of Dr. Marjan Farid of the Gavin Herbert Eye Institute at the University of California-Irvine (UCI) as Chair of […]
First Patient Treated in TECLens First-in-Human Clinical Study of Revolutionary Non-Invasive Vision Correction Technology
STAMFORD, Connecticut – February 24, 2026 – TECLens, Inc., a clinical-stage ophthalmic medical device company, announced today the treatment of the initial patient for its first-in-human clinical trial evaluating the company’s groundbreaking quantitative corneal crosslinking (qCXL™) technology for non-invasive refractive vision correction. The study marks a significant milestone in the development of the first vision correction platform designed to strengthen rather than compromise corneal integrity. The clinical study will evaluate the safety and […]
DefEYE Announces Publication of Multiple Peer-Reviewed Articles Highlighting Use of Biovance 3L Ocular
Sarasota, FL – February 23, 2026 – DefEYE, Inc, a privately held ophthalmics company focused on innovative placental-based biologic solutions for ocular surface disease and surgical applications, today announced the publication of two peer-reviewed articles highlighting the use of Biovance 3L Ocular, the only tri-layer decellularized basement membrane (DBM) in ocular surgery and in ocular […]
TearOptix Secures Strategic Funding to Transform Presbyopia Treatment and Announces Creation of Scientific Advisory Board
ATHERTON, Calif.–(BUSINESS WIRE)–TearOptix, Inc., a pioneering contact lens company developing advanced solutions for patients with presbyopia, today announced the completion of a strategic corporate financing round led by investors with deep expertise in ophthalmology. Presbyopia is the gradual loss of the eye’s ability to focus on nearby objects, affecting virtually everyone over the age of […]
DefEYE, Inc. Announces Investment from ExSight Ventures
Investment Supports Commercialization of Innovative Decellularized Placental Tissue Technology for Ocular Surface Disease and Surgical Management NEW YORK–(BUSINESS WIRE)–ExSight Ventures, a leading venture capital firm focused on transformational eye care innovations, today announced its investment in DefEYE, Inc., a rapidly growing ocular company developing decellularized placental-based tissue solutions to transform and personalize therapeutic approaches in […]
Sydnexis Announces UK Approval of Ryjunea® by Partner Santen to Slow Progression of Childhood Myopia
DEL MAR, Calif.–(BUSINESS WIRE)–Sydnexis, Inc., a biopharmaceutical company focused on pediatric progressive myopia (PPM), today noted its partner Santen’s announcement that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ryjunea® (low-dose atropine 0.1 mg/ml), the first MHRA approved treatment in the UK to slow the progression of myopia in children aged 3-14 years […]
Sydnexis Announces Topline Pivotal Data from Phase 3 STAR Trial of SYD-101 for Patients with Pediatric Progressive Myopia Presented at AMCP Nexus 2025
Largest global clinical trial in pediatric myopia met primary efficacy endpoint of proportion of patients with confirmed progression of -0.75D and key secondary endpoint of annual progression rate Treatment effects evident by month 12 and sustained through month 36; greatest treatment benefit observed in younger children, in participants with a history of myopia progression, or when administered […]
Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care
FLORHAM PARK, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, announced today a strategic partnership with DefEYE, Inc. (“DefEYE”), a newly established ophthalmic product and technology company. Celularity has executed an exclusive license & pricing arrangement with DefEYE on the backend […]
Aurion Biotech Achieves All Primary, Secondary, and Exploratory Endpoints in AURN001 Phase 1/2 CLARA Trial at 12 Months
Data strongly supports advancing high dose AURN001 regenerative cell therapy for patients with corneal endothelial disease to pivotal Phase 3 trial in H1 2026 Seattle, WA; Cambridge, MA; Tokyo, Japan – 18 October – Aurion Biotech, a clinical-stage regenerative medicine company with a mission to restore vision to millions of patients, today announced positive 12-month results from […]
